AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Shore Capital

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by equities research analysts at Shore Capital in a report released on Thursday, Digital Look reports.

A number of other brokerages also recently issued reports on AZN. Berenberg Bank reiterated a “buy” rating and issued a £150 ($195.26) price target on shares of AstraZeneca in a report on Monday, September 2nd. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Monday, September 16th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($143.19) price objective on shares of AstraZeneca in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of £101.62 ($132.29).

AstraZeneca Stock Down 1.5 %

LON AZN traded down GBX 150 ($1.95) during trading on Thursday, reaching GBX 9,772 ($127.21). 44,883,191 shares of the company’s stock traded hands, compared to its average volume of 4,123,456. The company’s 50 day simple moving average is £120.21 and its two-hundred day simple moving average is £121.65. AstraZeneca has a 12-month low of GBX 9,461 ($123.16) and a 12-month high of £133.88 ($174.28). The firm has a market cap of £151.47 billion, a price-to-earnings ratio of 3,102.22, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59.

Insiders Place Their Bets

In other news, insider Michel Demare acquired 2,000 shares of AstraZeneca stock in a transaction dated Friday, September 13th. The stock was purchased at an average cost of GBX 118 ($1.54) per share, for a total transaction of £2,360 ($3,072.12). Corporate insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.